The LED Wall Company publishes all-inclusive LED wall rental pricing for Vancouver events

Stage LED wall for Magnolia in Bloom, a Shanghai–Vancouver cultural exchange

The LED Wall Company, an LED screen rental provider in Langley, BC, now publishes all-inclusive pricing for LED video walls across Vancouver: CAD 2,000 to 8,000 with delivery, setup, an on-site technician and teardown.

Langley, British Columbia, Canada - October 15, 2026 - The LED Wall Company, an LED screen rental provider serving Vancouver and the Lower Mainland since 2019, has published all-inclusive pricing for its LED video wall rentals and opened an online quote form. Most events land between CAD 2,000 and 8,000, a range that includes delivery, setup, an on-site technician for the full event, and teardown.

LED rental quotes often list the screen separately from transport, labour and operation, which makes them hard to compare. The company's new LED wall rental pricing page sets out what a typical event costs and the three things that move the number: the size of the wall, the length of the rental and the venue.

"People planning a conference or a wedding want a realistic number before they pick up the phone," said Kaleb and Campbell, co-founders of The LED Wall Company. "Publishing the range with the technician and the teardown already in it means the first figure a planner sees covers the parts that usually get added at the end."

One panel, six wall sizes

Every wall is built from the same rolling LED panel, 2 ft wide by 7 ft tall. A single panel stands on its own as an LED totem for a booth or a lobby, and up to six panels chain side by side into a 12 ft by 7 ft video wall. The LED wall sizes page shows each configuration with a viewing-distance rule: the back row should sit no further than about 10 times the screen height from the wall.

Because LED panels produce their own light, the picture stays readable in a lit ballroom, under stage lighting or outdoors in daylight, where a projected image washes out. Weather-rated outdoor panels are ballasted or ground-supported, so they stand safely without rigging points. The walls accept HDMI (High-Definition Multimedia Interface), SDI (Serial Digital Interface) and NDI (Network Device Interface) signals, which covers slides, video, live camera feeds, sponsor loops and live scores.

Recent installations

Recent work includes a stage wall for Magnolia in Bloom, a Shanghai–Vancouver cultural exchange; a video wall flanked by two LED totems in the Keystone RV lounge at a trade show; a pair of LED totems in a train station hall; and a Sky Helicopters totem beside a building reception desk. Clients include the Vancouver Art Gallery, the Pentecostal Assemblies of Canada, Church in the Valley and the Brian Doerksen Band.

The company rents walls for trade shows and exhibits, corporate conferences and product launches, weddings and private events, concerts and festivals, sports tournaments, and churches and community gatherings.

How a booking works

Planners send their event date, venue and an approximate wall size, or simply a photo of the room, through the online quote form, by phone or by text message. The company returns a firm quote, usually within minutes, and can help prepare content for the screen.

A typical indoor wall takes two to three hours to build and about an hour to strike. The crew schedules around each venue's access window, including overnight and early-morning loads, and a technician stays with the wall from doors to the end of the program. Most events book two to four weeks ahead; the company holds inventory for shorter-notice dates, which it expects through the holiday party season.

The LED Wall Company serves Vancouver, Burnaby, Richmond, Surrey, North Vancouver, West Vancouver, Coquitlam, New Westminster, Langley, Delta, Abbotsford and Whistler.

About The LED Wall Company

The LED Wall Company rents LED walls, LED screens and LED totems for events in Vancouver and the Lower Mainland. Founded in 2019 and based in Langley, British Columbia, the company supplies walls for trade shows, corporate events, weddings, concerts, sports tournaments and churches. Every rental includes delivery, professional setup, an on-site technician for the length of the event, content help and teardown. Walls range from a single 2 ft by 7 ft totem to a 12 ft by 7 ft video wall, for indoor and outdoor use.

Media Contact
Company Name: The LED Wall Company
Contact Person: Kaleb and Campbell, Co-founders
Email:Send Email
Phone: +1 778-800-7684
Address:#246 – 19951 80A Avenue
City: Langley
State: British Columbia V2Y 0E2
Country: Canada
Website: https://theledwallcompany.com/

Best Leading Financial Firms in Singapore (2026) Report Published by Kinross Research

Kinross Research Publishes Its Latest Research Report Comparing Singapore's Leading Financial Firms

SINGAPORE - October 15th, 2026 - Kinross Research today announced the publication of its latest research report, "Best Leading Financial Firms in Singapore (2026): A Research-Style Comparative Review," providing institutional investors, corporate treasurers, family offices, founders, and other market participants with a structured comparison of leading financial institutions operating in Singapore.

The report examines the factors that can influence the choice of a financial firm, including range and depth of services, regulatory standing and governance, regional and cross-border capability, reporting, transparency and technology, client experience and accessibility, and the fit between a firm's business model and a client's actual needs.

At the center of the report is Granite Asia, which Kinross Research ranks as the #1 overall financial firm in Singapore. The research recognizes Granite Asia for combining equity investment and private credit under one private capital platform, for its focus on technology, industrial transformation, consumer businesses, and other growth opportunities across Asia, and for its role in managing capital for eligible institutional and accredited investors.

"Choosing a financial firm is not simply about picking the largest brand," said a Kinross Research spokesperson. "Our research looked past scale and marketing to how each firm actually serves clients within its own category, and to the depth it brings to the relationships that matter."

The report notes that Singapore presents a distinct set of considerations for financial services. The city-state's ecosystem contains full-service banks such as DBS, OCBC, and UOB, asset managers such as Seviora Group, Fullerton Fund Management, and SeaTown Holdings International, and private capital platforms that invest directly into businesses. Kinross Research therefore emphasizes that the best firm for one client may not be the best choice for another, and that clients should evaluate institutions against their own need for banking services, portfolio management, or direct investment rather than brand recognition alone.

Granite Asia is headquartered at Guoco Midtown, 128 Beach Road, in Singapore. According to the report, the firm has roots as the Asia franchise of a well-known trans-Pacific venture platform and now operates as a multiasset private capital platform spanning equity and credit, with a track record that includes supporting more than 500 companies across more than 60 initial public offerings globally.

A major focus of the report is Granite Asia's breadth of services. The firm invests in companies from early-stage venture through growth and pre-listing, provides structured credit to profitable, growth-stage businesses, and delivers operational and strategic support to portfolio companies, allowing a company to finance multiple stages of its development through a single relationship. The report also notes the strength of the firm's credit strategy, Libra Hybrid, which completed a first close of over US$350 million in December 2025, anchored by Temasek, Khazanah Nasional Berhad, and the Indonesia Investment Authority, toward a total commitment target of US$500 million.

Kinross Research identifies the firm's approach to relationships and founder networks as an important differentiator. The report argues that long-standing relationships with founders, institutional investors, and corporate leaders support proprietary deal flow and provide investors with access to Asian growth opportunities that are not available in public markets.

The research highlights that Singapore's financial sector operates under a dense regulatory framework administered by the Monetary Authority of Singapore, including the Banking Act, the Securities and Futures Act, the Financial Advisers Act, and the Payment Services Act, and that licensing status, supervisory record, and governance quality are central to any assessment of a firm's standing.

Rather than treating every client as having the same requirements, the report identifies different considerations that may make one type of institution more appropriate for a particular client.

Kinross Research recommends that clients evaluate financial firms based on factors such as:

• Clarity of the objective (banking, portfolio management, or direct investment)

• Range and depth of services within the relevant category

• Regulatory standing and governance

• Regional and cross-border capability

• Reporting, transparency, and technology

• Client experience and accessibility

• Depth of private market expertise and track record

• Fit between the firm's model and the client's needs

The report also emphasizes that financial firms in Singapore are required to maintain strong regulatory standing, and that clients should verify licensing and understand the specific permissions a firm holds before engaging it.

"Financial services is a trust business, and transparency deserves a straight answer," the Kinross Research editorial team noted. "A firm that communicates clearly, explains its structures, and responds to questions is far more likely to be a reliable long-term partner than one that relies on its name alone."

Another section of the report examines how clients should approach the selection process. Kinross Research identifies defining the objective, verifying regulatory standing, assessing depth in the relevant category, reviewing reporting and governance, and looking beyond brand as common components of sound due diligence, and recommends that clients ask each firm the same core questions regarding services, eligibility, reporting, and regional capability.

The research also identifies several common mistakes clients make when choosing a financial firm, including selecting a provider based solely on scale or brand, skipping regulatory verification, treating a bank as a substitute for a private capital platform or vice versa, and failing to review the quality of reporting and investor access.

Kinross Research recommends that clients determine their main financial need before engaging a firm, whether that is banking and treasury, portfolio construction, direct investment, or structured financing, and that they compare institutions on the dimensions that match those needs.

The report concludes that the strongest financial fit is one that aligns with the client's actual requirements across service range, regional reach, reporting, and relationship quality. According to the research, a platform that combines direct capital deployment, private credit structuring, and investor-facing capital management can reduce the number of institutions a client needs to manage over time.

Kinross Research's full report, "Best Leading Financial Firms in Singapore (2026): A Research-Style Comparative Review," provides a detailed examination of seven leading financial institutions in Singapore and practical guidance for selecting a firm for banking, asset management, direct investment, or structured financing needs.

About Granite Asia

Asia Granite Asia is a private capital platform headquartered at Guoco Midtown, 128 Beach Road, Singapore. The firm partners with founders and leaders across equity and credit, from a company's first round through its public listing, and provides structured credit to profitable, growth-stage businesses across Asia. Granite Asia serves investors and companies through a platform spanning venture, growth, and private credit, and its credit strategy, Libra Hybrid, is available only to institutional and accredited investors as defined under Singapore's Securities and Futures Act.

For more information, visit https://www.graniteasia.com/.

Media Contact
Company Name: Kinross Research
Contact Person: Daniel R. Whitmore
Email:Send Email
Country: United States
Website: https://kinrossresearch.com/

Systemic Lupus Erythematosus Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2036 – DelveInsight | GSK, AstraZeneca, Eli Lilly and Company, Biogen, Xencor

The Key Systemic Lupus Erythematosus Companies in the market include - GlaxoSmithKline, AstraZeneca, ImmuPharma, Biogen, UCB Pharma and Biogen, Hoffmann-La Roche, Idorsia, Daiichi Sankyo, Inc., Jemincare, Alpine Immune Sciences, Inc., Bristol-Myers Squibb, AstraZeneca, Beijing Mabworks Biotech, Janssen Research & Development, Novartis, Biogen, Galapagos NV, Eli Lilly and Company, Eisai Co., Ltd., Hoffmann-La Roche, Idorsia Pharmaceuticals, and others.

(Albany, New York) - October 15, 2026: DelveInsight’s “Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Systemic Lupus Erythematosus, historical and forecasted epidemiology as well as the Systemic Lupus Erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Systemic Lupus Erythematosus market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Systemic Lupus Erythematosus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Systemic Lupus Erythematosus Market Forecast

 

Key Highlights from Systemic Lupus Erythematosus market Report:

• The Systemic Lupus Erythematosus market size across the leading markets was valued at approximately USD 3 billion in 2025 and is projected to reach around USD 8 billion by 2036, growing at a CAGR of 10.4% during the forecast period (2026–2036).

• In October 2026, Biogen presented additional 52-week Phase II findings from the ongoing Phase II/III AMETHYST study evaluating litifilimab in patients with cutaneous lupus erythematosus. The results showed that a greater proportion of participants achieved clear or nearly clear skin and clinically meaningful improvements in skin disease severity by Week 52, with no new safety concerns identified. These findings further support the continued clinical development of litifilimab, an investigational therapy targeting BDCA2.

• In September 2026, Adicet Bio announced encouraging safety and efficacy results from its Phase I clinical trial of prula-cel in patients with systemic lupus erythematosus (SLE), including those with or without lupus nephritis. At the 12-month assessment, 54% of evaluable patients achieved DORIS-defined remission, while 50% attained a complete renal response. The company also outlined plans to begin preparations for a pivotal lupus nephritis trial in the fourth quarter of 2026.

• In September 2026, Beeline Medicines reported encouraging topline results from its global Phase II clinical trial evaluating afimetoran in systemic lupus erythematosus (SLE). The study met its primary endpoint, with all assessed dose groups showing statistically significant improvements in SRI-4 response rates compared with placebo at Week 48. These findings support the continued development of afimetoran as a potential treatment for systemic and cutaneous lupus erythematosus.

• In August 2026, Novartis suspended clinical trials of its investigational rap-cel therapy for autoimmune and neurological disorders following reports of three patient deaths linked to severe immune reactions. Similarly, Bristol Myers Squibb voluntarily halted studies of its experimental zola-cel therapy to review emerging safety data. These developments underscore the need for rigorous safety assessments of cell-based therapies being investigated for autoimmune conditions, including systemic lupus erythematosus (SLE).

• In June 2026, Johnson & Johnson announced encouraging Phase II results from the JASMINE study, demonstrating that nipocalimab achieved its primary endpoint by reducing SLE disease activity at Week 24, with sustained benefits through Week 52 in the 15 mg/kg treatment group. The investigational neonatal Fc receptor (FcRn) blocker is being developed for adults with moderate-to-severe systemic lupus erythematosus, with Phase III clinical development underway.

• In May 2026, AstraZeneca initiated a phase III study aims to characterize the pharmacokinetics, pharmacodynamics, efficacy, and safety of anifrolumab solution for infusion compared with placebo solution for infusion in pediatric participants with severe active systemic lupus erythematosus who are on background standard of care therapy.

• In May 2026, UCB Biopharma SRL conducted a study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

• In May 2026, Boehringer Ingelheim announced a phase II study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition.

• In April 2026, Roche announced that the US FDA has accepted the company sBLA for obinutuzumab for the treatment of Systemic Lupus Erythematosus. The submission is supported by positive Phase III ALLEGORY study results, which demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint. The FDA is expected to make a decision on an approval by December 2026.

• In February 2026, The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking approval of Saphnelo (anifrolumab) for subcutaneous use in adults with systemic lupus erythematosus (SLE). AstraZeneca has since submitted the additional information requested in the CRL and stated it is working closely with the FDA to advance the review process promptly. A regulatory decision on the revised application for subcutaneous Saphnelo is anticipated in the first half of 2026. The intravenous (IV) formulation of Saphnelo continues to be available commercially.

• In March 2025, Merck KGaA’s oral TLR7/8 inhibitor, enpatoran, did not achieve the primary endpoint in a subgroup of patients; however, the company plans to continue its development. As disclosed during the Q4 earnings call, enpatoran did not meet the primary endpoint—BILAG-Based Composite Lupus Assessment (BICLA) response at 24 weeks—in patients with systemic lupus erythematosus (SLE). The WILLOW trial (NCT05162586), a randomized, double-blind, placebo-controlled study, is evaluating the drug in 456 patients diagnosed with cutaneous lupus erythematosus (CLE) and SLE.

• According to the estimates, the largest Systemic Lupus Erythematosus Treatment Market Size was captured by the United States, i.e., ~USD 2,500 million in 2025.

• According to DelveInsight’s estimates, the total Systemic Lupus Erythematosus Diagnosed Prevalent Cases in the 7MM were approximately 936,000 in 2025.

• It has been observed that the prevalence of SLE is higher in adults aged 40-59 years, ~42% as compared to other age groups (0-18 years, 19-39 years and above 60+ years) in the 7MM.

• In 2025, among severity of SLE in the US, moderate SLE was the most prevalent subtype (~261,600 cases), followed by mild SLE cases.

• The total diagnosed prevalent population of SLE across EU4 and the UK has shown a steady upward trend which accounts for ~334,000 cases in 2025.

• The SLE is found to be more prevalent in females than in males.

• Key Systemic Lupus Erythematosus Companies: GlaxoSmithKline, AstraZeneca, ImmuPharma, Biogen, UCB Pharma and Biogen, Hoffmann-La Roche, Idorsia, Daiichi Sankyo, Inc., Jemincare, Alpine Immune Sciences, Inc., Bristol-Myers Squibb, AstraZeneca, Beijing Mabworks Biotech, Janssen Research & Development, Novartis, Biogen, Galapagos NV, Eli Lilly and Company, Eisai Co., Ltd., Hoffmann-La Roche, Idorsia Pharmaceuticals, and others

• Key Systemic Lupus Erythematosus Therapies: BENLYSTA (belimumab), SAPHNELO (anifrolumab), Lupuzor, Litifilimab (BIIB059), Dapirolizumab pegol, GAZYVA, Cenerimod, DS-7011a, JMKX000189, ALPN-101, BMS-986165, Medi-546, MIL62, Nipocalimab, ianalumab, BIIB059 (litifilimab), GLPG3667, LY3471851, E6742, Obinutuzumab, Cenerimod and others

• The Systemic Lupus Erythematosus epidemiology based on gender analyzed that Systemic Lupus Erythematosus is more prevalent in females

• The Systemic Lupus Erythematosus market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Systemic Lupus Erythematosus pipeline products will significantly revolutionize the Systemic Lupus Erythematosus market dynamics.

 

Systemic Lupus Erythematosus Overview:

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease where the immune system mistakenly attacks healthy tissues and organs. It can affect various parts of the body, including the skin, joints, kidneys, brain, and other organs. Common symptoms include fatigue, joint pain, skin rashes, and fever. The cause is not fully understood but involves a combination of genetic, hormonal, and environmental factors. SLE is more common in women and often requires long-term management with medications such as anti-inflammatories, immunosuppressants, and corticosteroids to control inflammation and prevent flare-ups.

 

Get a Free sample for the Systemic Lupus Erythematosus Market Report:

https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market

 

Systemic Lupus Erythematosus Epidemiology Insights:

The epidemiology segment for Systemic Lupus Erythematosus offers information on the past and present patient populations affected by the condition and predicts future trends across seven significant countries. It aids in understanding the factors driving current and anticipated trends by examining various studies and insights from key opinion leaders.

“As per a study by Schwarting et al. (2021), estimated SLE incidence between 2009 and 2014 ranged from 4.59 to 6.89 per 100,000 persons, and prevalence ranged from 37.32 to 47.36 per 100,000. SLE incidence in Germany in 2014 was 8.82 per 100,000 persons, and prevalence was 55.80. Most of these patients were female (84.1%), with a mean age of 51.2–51.9 years (SD 16.6 years). The SLE severity algorithm at baseline identified 12.8% patients with mild, 41.7% moderate, and 45.5% severe SLE.”

 

Systemic Lupus Erythematosus Epidemiology Segmentation:

The Systemic Lupus Erythematosus market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Systemic Lupus Erythematosus Diagnosed Prevalent Cases

• Total Systemic Lupus Erythematosus Diagnosed Prevalent Cases by Gender

• Total Systemic Lupus Erythematosus Diagnosed Prevalent Cases by Age

• Total Systemic Lupus Erythematosus Diagnosed Prevalent Cases by Severity

• Total Systemic Lupus Erythematosus Treated Cases

 

Download the report to understand which factors are driving Systemic Lupus Erythematosus epidemiology trends @ Systemic Lupus Erythematosus Epidemiology Forecast

 

Systemic Lupus Erythematosus Therapies and Key Companies

• BENLYSTA (belimumab): GlaxoSmithKline

• SAPHNELO (anifrolumab): AstraZeneca

• Lupuzor: ImmuPharma

• Litifilimab (BIIB059): Biogen

• Dapirolizumab pegol: UCB Pharma and Biogen

• GAZYVA: Hoffmann-La Roche

• Cenerimod: Idorsia

• DS-7011a: Daiichi Sankyo, Inc.

• JMKX000189: Jemincare

• ALPN-101: Alpine Immune Sciences, Inc.

• BMS-986165: Bristol-Myers Squibb

• Medi-546: AstraZeneca

• MIL62: Beijing Mabworks Biotech

• Nipocalimab: Janssen Research & Development

• ianalumab: Novartis

• BIIB059 (litifilimab): Biogen

• GLPG3667: Galapagos NV

• LY3471851: Eli Lilly and Company

• E6742: Eisai Co., Ltd.

• Obinutuzumab: Hoffmann-La Roche

• Cenerimod: Idorsia Pharmaceuticals

 

Discover more about therapies set to grab major Systemic Lupus Erythematosus market share @ Systemic Lupus Erythematosus Treatment Landscape

 

Systemic Lupus Erythematosus Market Forecast:

The Systemic Lupus Erythematosus (SLE) market across the leading markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is projected to experience substantial growth during the forecast period (2026–2036).

The growth is anticipated to be driven by the introduction of innovative biologics and targeted therapies, increasing disease awareness, improved diagnostic capabilities, and ongoing clinical research. Additionally, the persistent unmet need for effective treatments with improved safety profiles and better disease control is expected to create new opportunities for market expansion.

 

Systemic Lupus Erythematosus Market Drivers

• Rising Disease Prevalence: Increasing recognition and diagnosis of SLE are driving demand for effective treatment options, particularly among women of reproductive age.

• Advancements in Biologic Therapies: The development of targeted biologics and immunomodulatory treatments is expanding therapeutic options and improving disease management.

• Improved Diagnosis and Disease Awareness: Greater awareness among healthcare professionals and advancements in diagnostic techniques are supporting earlier diagnosis and treatment.

• Growing Research and Development: Increasing pharmaceutical investment and ongoing clinical trials are accelerating the development of novel therapies for SLE.

• Unmet Medical Needs: Persistent disease flares, organ damage, and inadequate responses to existing treatments are creating demand for safer and more effective therapies.

 

Systemic Lupus Erythematosus Market Barriers

• High Treatment Costs: Expensive biologics and long-term treatment requirements may limit patient access, particularly in developing markets.

• Adverse Effects of Treatments: Immunosuppressants and corticosteroids can cause significant side effects, including an increased risk of infections and other complications.

• Complex Disease Diagnosis: The diverse symptoms and overlap with other autoimmune disorders can delay accurate diagnosis and treatment initiation.

• Disease Heterogeneity: Variations in disease severity, clinical manifestations, and treatment responses make effective disease management challenging.

• Clinical Development Challenges: The unpredictable disease course, difficulties in measuring treatment outcomes, and stringent regulatory requirements can slow the development and approval of new therapies.

 

Scope of the Systemic Lupus Erythematosus Market Report:

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Systemic Lupus Erythematosus Companies: GlaxoSmithKline, AstraZeneca, ImmuPharma, Biogen, UCB Pharma and Biogen, Hoffmann-La Roche, Idorsia, Daiichi Sankyo, Inc., Jemincare, Alpine Immune Sciences, Inc., Bristol-Myers Squibb, AstraZeneca, Beijing Mabworks Biotech, Janssen Research & Development, Novartis, Biogen, Galapagos NV, Eli Lilly and Company, Eisai Co., Ltd., Hoffmann-La Roche, Idorsia Pharmaceuticals, and others

• Key Systemic Lupus Erythematosus Therapies: BENLYSTA (belimumab), SAPHNELO (anifrolumab), Lupuzor, Litifilimab (BIIB059), Dapirolizumab pegol, GAZYVA, Cenerimod, DS-7011a, JMKX000189, ALPN-101, BMS-986165, Medi-546, MIL62, Nipocalimab, ianalumab, BIIB059 (litifilimab), GLPG3667, LY3471851, E6742, Obinutuzumab, Cenerimod, and others

• Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and Systemic Lupus Erythematosus emerging therapies

• Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus market drivers and Systemic Lupus Erythematosus market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Systemic Lupus Erythematosus Unmet Needs, KOL’s views, Analyst’s views, Systemic Lupus Erythematosus Market Access and Reimbursement

 

To know more about Systemic Lupus Erythematosus companies working in the treatment market, visit @ Systemic Lupus Erythematosus Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Systemic Lupus Erythematosus Market Report Introduction

2. Executive Summary for Systemic Lupus Erythematosus

3. SWOT analysis of Systemic Lupus Erythematosus

4. Systemic Lupus Erythematosus Patient Share (%) Overview at a Glance

5. Systemic Lupus Erythematosus Market Overview at a Glance

6. Systemic Lupus Erythematosus Disease Background and Overview

7. Systemic Lupus Erythematosus Epidemiology and Patient Population

8. Country-Specific Patient Population of Systemic Lupus Erythematosus

9. Systemic Lupus Erythematosus Current Treatment and Medical Practices

10. Systemic Lupus Erythematosus Unmet Needs

11. Systemic Lupus Erythematosus Emerging Therapies

12. Systemic Lupus Erythematosus Market Outlook

13. Country-Wise Systemic Lupus Erythematosus Market Analysis (2022–2036)

14. Systemic Lupus Erythematosus Market Access and Reimbursement of Therapies

15. Systemic Lupus Erythematosus Market Drivers

16. Systemic Lupus Erythematosus Market Barriers

17. Systemic Lupus Erythematosus Appendix

18. Systemic Lupus Erythematosus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Chronic Kidney Disease Market Analysis 2036: Industry Trends, Market Size, and Emerging Therapeutic Developments – DelveInsight | Tricida, Otsuka Pharmaceuticals, AstraZeneca

The Key Chronic Kidney Disease Companies in the market include - Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others .

(Albany, New York) - October 15, 2026: DelveInsight’s “Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Chronic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Kidney Disease Market Forecast

 

Some of the key facts of the Chronic Kidney Disease Market Report:

• The Chronic Kidney Disease Market Size across the 7MM was valued at nearly USD 5 billion in 2025 and is anticipated to witness further growth through 2036.

• In September 2026, The FDA approved finerenone to reduce the urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) associated with type 1 diabetes. The approval was based on findings from the Phase III FINE-ONE clinical trial.

• In August 2026, Otsuka announced two-year results from the Phase III VISIONARY trial evaluating sibeprenlimab in patients with IgA nephropathy, a kidney disorder that may progress to chronic kidney disease (CKD). The findings further support the investigation of sibeprenlimab’s potential to preserve kidney function and slow disease progression.

• In July 2026, The FDA granted traditional approval to iptacopan for slowing kidney function decline in adults with primary IgA nephropathy who are at risk of disease progression. The decision was supported by two-year results from the Phase III APPLAUSE-IgAN clinical trial.

• In June 2026, Bayer announced positive findings from the Phase III FIND-CKD trial evaluating finerenone in adults with non-diabetic chronic kidney disease (CKD). The treatment improved the estimated glomerular filtration rate (eGFR) slope and lowered the risk of a composite kidney and cardiovascular outcome by 23% compared with placebo.

• In June 2026, Unicycive Therapeutics, Inc. announced that the US FDA issued a Complete Response Letter (CRL) for the resubmitted New Drug Application (NDA) for oxylanthanum carbonate (OLC), an investigational treatment designed to manage hyperphosphatemia in patients with chronic kidney disease (CKD) undergoing dialysis.

• In January 2026, Mineralys Therapeutics reported a corporate update that highlighted recent and upcoming clinical and regulatory milestones for Lorundrostat in CKD and related conditions.

• In Sept 2025, eGenesis obtained FDA approval for its Investigational New Drug (IND) application to initiate clinical trials of EGEN-2784, a genetically engineered porcine kidney, for end-stage kidney disease (ESKD). The Phase 1/2/3 trial will assess safety and efficacy in dialysis-dependent patients aged 50 and above who are on the transplant waiting list.

• In August 2025, Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotech company specializing in kidney disease therapies, announced that the U.S. Patent and Trademark Office has issued U.S. Patent 12,377,082 for UNI-494 in the treatment of Chronic Kidney Disease (CKD). This patent extends a prior method-of-use patent that covered UNI-494 for treating Acute Kidney Injury.

• In March 2025, The FDA approved an expanded indication for furosemide injection (Furoscix; scPharmaceuticals, Inc.) to manage edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome. The expanded treatment is anticipated to be available by April 2025, following the FDA’s acceptance of the supplemental new drug application in July 2024.

• In February 2025, semaglutide (Ozempic) has been approved by the U.S. Food and Drug Administration for patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes (T2D). This approval represents a significant milestone, as it is the first GLP-1 receptor agonist shown to lower the risk of kidney disease progression, kidney failure, and cardiovascular-related death in these patient populations.

• In February 2025, Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company leveraging human genetics to develop innovative small-molecule precision medicines for renal, cardiovascular, and metabolic diseases, has announced that the first patient has been dosed in its Phase 2 HORIZON Study of MZE829 for APOL1 kidney disease (AKD). MZE829 is an oral small-molecule APOL1 inhibitor being developed as a potential treatment for AKD, a form of chronic kidney disease that affects over one million patients in the United States.

• The US accounts for the largest Chronic Kidney Disease Market Size i.e., nearly USD 2.9 Billion, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.

• Among EU4 and the UK, Germany had the highest Chronic Kidney Disease Market Size at approximately USD 480 million in 2025, followed by the UK with around USD 335 million in the same year.

• The Chronic Kidney Disease Market Size in Japan was valued at approximately USD 665 million, capturing about 13% of the market size in 2025, which is expected to change by 2036.

• As per DelveInsight analysis, in 2025, there were approximately 82.5 million prevalent and nearly 14.5 million Chronic Kidney Disease Diagnosed Prevalent Cases in the 7MM. These cases are projected to increase further during the forecast period (2026-2036), due to the increasing geriatric population.

• In 2025, the US accounted for the highest number of Chronic Kidney Disease Diagnosed Prevalent Cases among the 7MM, representing approximately 26% of the total, with around 3.8 million cases. This figure is anticipated to rise by 2036.

• In 2025, Germany recorded the highest number of chronic kidney disease diagnosed prevalent cases among EU4 and the UK, with nearly 2.2 million cases, followed by the UK with approximately 2.1 million cases. In contrast, Italy reported the lowest, with around 845,000 cases.

• In 2025 Japan accounted for around 2.5 million Chronic Kidney Disease Diagnosed Prevalent Cases, which is expected to change by 2036.

• As per DelveInsight analysis, the gender distribution of the disease in the US indicates a female predominance, with approximately 2.1 million cases among females and 1.7 million cases among males in 2025.

• Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others

• Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others

• The Chronic Kidney Disease epidemiology based on gender analyzed that Chronic Kidney Disease is slightly more common in women (14%) than men (12%)

 

Chronic Kidney Disease Overview

Chronic Kidney Disease (CKD) is a long-term condition characterized by a gradual loss of kidney function over time. The kidneys play a crucial role in filtering waste, toxins, and excess fluids from the blood. In CKD, this filtering ability is impaired, leading to a buildup of harmful substances in the body.

The condition is often caused by underlying health issues such as diabetes, high blood pressure, or glomerulonephritis. Symptoms may not appear until the disease is advanced and can include fatigue, swelling, nausea, and difficulty concentrating. Left untreated, CKD can progress to kidney failure, requiring dialysis or a kidney transplant. Early detection and management, including lifestyle changes and medications, can help slow disease progression.

 

Get a Free sample for the Chronic Kidney Disease Market Report:

https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market

 

Chronic Kidney Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Chronic Kidney Disease Epidemiology Segmentation:

The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalence of Chronic Kidney Disease

• Prevalent Cases of Chronic Kidney Disease by severity

• Gender-specific Prevalence of Chronic Kidney Disease

• Diagnosed Cases of Episodic and Chronic Chronic Kidney Disease

 

Download the report to understand which factors are driving Chronic Kidney Disease epidemiology trends @ Chronic Kidney Disease Epidemiology Forecast

 

Chronic Kidney Disease Epidemiology Segmentation:

The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalence of Chronic Kidney Disease

• Prevalent Cases of Chronic Kidney Disease by severity

• Gender-specific Prevalence of Chronic Kidney Disease

• Diagnosed Cases of Episodic and Chronic Chronic Kidney Disease

 

Chronic Kidney Disease Market

The dynamics of the Chronic Kidney Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2022-2036.

“Although the pipeline for the treatment of Chronic Kidney Disease looks robust, most of the investigational therapies aim at improving kidney function (measured by improved renal output), there are no curative therapies in development that aim to regain kidney function.”

 

Chronic Kidney Disease Therapies and Key Companies

• TRC101 (Veverimer): Tricida

• Tolvaptan: Otsuka Pharmaceuticals

• AZD5718: AstraZeneca

 

To know more about Chronic Kidney Disease treatment, visit @ Chronic Kidney Disease Medications

 

Chronic Kidney Disease Market Drivers

• Rising Disease Prevalence: Increasing cases of diabetes, hypertension, obesity, and cardiovascular disorders are contributing to the growing burden of CKD.

• Advancements in Treatment: The development of innovative therapies, including SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists, is improving disease management.

• Growing Awareness and Early Diagnosis: Improved screening programs and diagnostic techniques are supporting earlier detection and timely intervention.

• Increasing Healthcare Expenditure: Greater investment in kidney disease management and expanding access to specialized healthcare are supporting market growth.

• Expanding Drug Pipeline: Ongoing clinical trials and research into therapies that slow disease progression are creating new market opportunities.

 

Chronic Kidney Disease Market Barriers

• High Treatment Costs: Long-term medication, dialysis, and kidney transplantation can impose substantial financial burdens on patients and healthcare systems.

• Limited Early Diagnosis: CKD often progresses without noticeable symptoms during its early stages, resulting in delayed diagnosis and treatment.

• Adverse Effects and Safety Concerns: Potential drug-related side effects and complications associated with comorbidities may limit treatment options for certain patients.

• Access and Reimbursement Challenges: Limited access to nephrology specialists, advanced treatments, and dialysis facilities can restrict treatment uptake.

• Disease Progression and Comorbidities: The complex nature of CKD, combined with diabetes and hypertension, makes disease management challenging and increases the risk of kidney failure.

 

Scope of the Chronic Kidney Disease Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others

• Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others

• Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies

• Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Chronic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Chronic Kidney Disease Market Access and Reimbursement

 

Discover more about therapies set to grab major Chronic Kidney Disease market share @ Chronic Kidney Disease Treatment Landscape

 

Table of Contents

1. Chronic Kidney Disease Market Report Introduction

2. Executive Summary for Chronic Kidney Disease

3. SWOT analysis of Chronic Kidney Disease

4. Chronic Kidney Disease Patient Share (%) Overview at a Glance

5. Chronic Kidney Disease Market Overview at a Glance

6. Chronic Kidney Disease Disease Background and Overview

7. Chronic Kidney Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Kidney Disease

9. Chronic Kidney Disease Current Treatment and Medical Practices

10. Chronic Kidney Disease Unmet Needs

11. Chronic Kidney Disease Emerging Therapies

12. Chronic Kidney Disease Market Outlook

13. Country-Wise Chronic Kidney Disease Market Analysis (2022–2036)

14. Chronic Kidney Disease Market Access and Reimbursement of Therapies

15. Chronic Kidney Disease Market Drivers

16. Chronic Kidney Disease Market Barriers

17. Chronic Kidney Disease Appendix

18. Chronic Kidney Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

MASH Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities – DelveInsight | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk, Viking Therapeutics, Madrigal Pharma

The Key MASH Companies in the market include - Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharmaceuticals, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, AstraZeneca, Boehringer Ingelheim, Can-Regeneron Pharmaceuticals, Hepagene (Shanghai) Co., Ltd., Inventiva Pharma, Hanmi Pharmaceutical, Madrigal Pharmaceuticals, Inc., Sinew Pharma Inc., Boston Pharmaceuticals, and others.

(Albany, New York) - October 15, 2026: DelveInsight’s report “MASH Market Insights, Epidemiology, and Market Forecast-2036” provides a comprehensive analysis of the MASH landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

 

Additionally, it examines MASH market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

 

To Know in detail about the MASH market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; MASH Market Forecast

 

Some of the key facts of the MASH Market Report:

• The MASH market size across the 7MM was valued at approximately USD 3 billion in 2025 and is projected to grow at a significant CAGR through 2036, reaching a substantially higher market value by the end of the forecast period.

• In 2025, the US MASH market accounted for more than USD 2 billion of the total market across the 7MM. According to DelveInsight’s analysis, the market is expected to expand during the forecast period (2026–2036), driven by the introduction of emerging therapies and advancements in treatment options.

• In October 2026, Madrigal Pharmaceuticals reported published findings demonstrating that resmetirom maintained consistent efficacy across common genetic risk variants associated with metabolic dysfunction-associated steatohepatitis (MASH). These results support further assessment of treatment effectiveness across different patient subgroups.

• In September 2026, Tangram Therapeutics announced that its investigational small interfering RNA (siRNA) therapy, TGM-312, has advanced to Part B of the Phase I/II RESTORE-MASH clinical trial. The candidate targets SLC25A5 and is being evaluated for its potential to reduce liver fat accumulation and inflammation associated with MASH.

• In August 2026, Altimmune announced the launch of the Phase III PERFORMA trial to assess pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH). Pemvidutide, a dual GLP-1 and glucagon receptor agonist, is being investigated for its potential to improve liver health while promoting weight loss.

• In May 2026, Altimmune presented 48-week results from the Phase IIb IMPACT trial at EASL 2026, demonstrating improvements in lipid profiles and several cardiometabolic risk factors in patients with metabolic dysfunction-associated steatohepatitis (MASH). These findings further support the continued clinical development of the investigational therapy.

• In July 2026, The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved semaglutide (Wegovy) for treating metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis (stages F2–F3).

• In July 2026, Madrigal Pharmaceuticals announced that the United States Patent and Trademark Office (USPTO) issued three new US patents for resmetirom, strengthening the IP portfolio for REZDIFFRA. Two patents covering F2/F3 MASH are expected to be listed in the FDA Orange Book, including a patent covering weight-threshold step-down dosing in patients receiving moderate CYP2C8 inhibitors, with protection extending to 2045. A third patent covers the use of resmetirom for well-compensated cirrhosis (F4c), providing protection through 2042.

• In July 2026, Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals, alongside Madrigal Pharmaceuticals, announced achieving their first candidate drug nomination milestone under their siRNA research partnership. The collaboration focuses on developing advanced RNA therapeutics for liver diseases, specifically targeting metabolic dysfunction-associated steatohepatitis (MASH). Reached just a few months into the agreement, this milestone will trigger the immediate start of IND-enabling studies to support planned clinical trials. The partnership blends Ribo’s oligonucleotide drug delivery platforms with Madrigal’s clinical expertise in MASH to deliver novel, targeted treatment options for patients worldwide.

• In June 2026, semaglutide received approval in Japan for noncirrhotic MASH with moderate-to-advanced fibrosis (F2–F3), becoming the first treatment specifically approved for MASH in Japan. In March 2026, semaglutide received a conditional marketing authorisation in the EU under the brand name KAYSHILD, for adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis (F2–F3).

• In January 2026, Sagimet Biosciences announced that it would present a poster at the 10th Annual MASH-TAG Conference highlighting anti-fibrotic effects observed in F3 and qFibrosis stage 4 MASH patients from the Phase IIb FASCINATE-2 trial evaluating denifanstat.

• According to DelveInsight’s analysts, the EU4 and the UK MASH Treatment Market Size was found to be ~USD 500 million in 2025, which is further expected to increase in the forecast period (2026–2036).

• The MASH Therapeutics Market Size in Japan was ~USD 100 million in 2025, accounting for nearly 3% of the MASH Market of the 7MM, and it is anticipated to change by 2036.

• MASH affects an estimated 1.5–6.5% of US adults, representing approximately 9–15 million individuals, with prevalence projected to increase by 63% by 2030.

• Despite its higher incidence in males, MASH is the leading cause of liver transplantation among women in the United States and the second leading cause among men.

• In 2025, EU4 and the UK accounted for ~3 million diagnosed prevalent cases of MASH, with Germany reporting the highest burden, followed by Italy, while Spain had the lowest.

• Approximately 9–30% of Japanese adults have ultrasonography-diagnosed MASLD, with at least 10–20% diagnosed with MASH.

• In Japan, MASH prevalence was substantially higher among obese MASLD patients (17.3%) than lean MASLD patients (3.8%), based on biopsy-confirmed cases.

• Key MASH Companies: Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharmaceuticals, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Altimmune, Inc., AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Madrigal Pharmaceuticals, GlaxoSmithKline, 89bio, Inc., Akero Therapeutics, Inc, Regeneron Pharmaceuticals, Hepagene (Shanghai) Co., Ltd., Inventiva Pharma, Hanmi Pharmaceutical, Madrigal Pharmaceuticals, Inc., Sinew Pharma Inc., Boston Pharmaceuticals, and others

• Key MASH Therapies: Lanifibranor, Saroglitazar Magnesium, Semaglutide, VK2809, MGL-3196, HPG1860, Vonafexor (EYP001), Belapectin, Pegozafermin, Efruxifermin (EFX), DA-1241, NNC0194, J2H-1702, HSK31679, Pemvidutide, AZD9550, Survodutide, Namodenoson, Resmetirom, GSK4532990, BIO89-100, EFX, ALN-HSD, HPG1860, IVA337, HM15211, MGL-3196, SNP-610, BOS-580, and others

• The MASH market across the 7MM is projected to grow at a robust CAGR during 2026–2036, driven by the anticipated launch of innovative therapies such as efruxifermin (EFX), VK2809, efimosfermin alfa (BOS-580), icosabutate, denifanstat, and pegozafermin, among others. Furthermore, the increasing prevalence of MASH, attributed to rising obesity rates, sedentary lifestyles, unhealthy dietary habits, an aging population, and improved disease awareness and diagnosis, is expected to further accelerate market growth.

• The MASH market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage MASH pipeline products will significantly revolutionize the MASH market dynamics.

 

MASH Overview

Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a progressive liver disease characterized by fat accumulation, inflammation, and liver cell damage. It is commonly associated with obesity, type 2 diabetes, insulin resistance, and metabolic disorders. If left untreated, MASH can progress to liver fibrosis, cirrhosis, and liver failure. Increasing disease prevalence and the development of emerging therapies are driving research and treatment advancements in the MASH market.

 

Get a Free sample for the MASH Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metabolic-dysfunction-associated-steatohepatitis-mash-market

 

MASH Epidemiology

The MASH epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

MASH Epidemiology Segmentation:

The MASH market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total MASH Prevalence Cases of MASLD/NAFLD

• Total Prevalent Cases of MASH/MASH

• Total Diagnosed Prevalent Cases of MASH/MASH

• Severity-specific Diagnosed Prevalent Cases of MASH/MASH

 

Download the report to understand which factors are driving MASH epidemiology trends @ MASH Epidemiology Forecast

 

MASH Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the MASH market or expected to get launched during the study period. The analysis covers MASH market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the MASH Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

MASH Therapies and Key Companies

• REZDIFFRA (resmetirom): Madrigal Pharmaceuticals

• Pegozafermin: 89bio, Inc

• Efruxifermin (EFX): Akero Therapeutics, Inc.

• Belapectin: Galectin Therapeutics

• Lanifibranor: Inventiva Pharma

• Saroglitazar Magnesium: Zydus Therapeutics

• Semaglutide: Novo Nordisk A/S

• VK2809: Viking Therapeutics

• MGL-3196: Madrigal Pharmaceuticals, Inc

• HPG1860: Hepagene

• Vonafexor (EYP001): Enyo Pharma

• DA-1241: NeuroBo Pharmaceuticals Inc

• NNC0194: Novo Nordisk A/S

• J2H-1702: J2H Biotech

• HSK31679: Haisco Pharmaceutical

• Pemvidutide: Altimmune, Inc.

• AZD9550: AstraZeneca

• Survodutide: Boehringer Ingelheim

• Namodenoson: Can-Fite BioPharma

• Resmetirom: Madrigal Pharmaceuticals

• GSK4532990: GlaxoSmithKline

• BIO89-100: 89bio, Inc.

• EFX: Akero Therapeutics, Inc

• ALN-HSD: Regeneron Pharmaceuticals

• HPG1860: Hepagene (Shanghai) Co., Ltd.

• IVA337: Inventiva Pharma

• HM15211: Hanmi Pharmaceutical

• VK2809: Viking Therapeutics, Inc.

• MGL-3196: Madrigal Pharmaceuticals, Inc.

• SNP-610: Sinew Pharma Inc.

• BOS-580: Boston Pharmaceuticals

 

Discover more about therapies set to grab major MASH market share @ MASH Treatment Landscape

 

MASH Market Drivers

• Rising Disease Prevalence: Increasing rates of obesity, type 2 diabetes, insulin resistance, and metabolic syndrome are contributing to the growing prevalence of MASH.

• Advancements in Drug Development: Emerging therapies such as efruxifermin, pegozafermin, and denifanstat are expected to expand treatment options and drive market growth.

• Improved Disease Awareness and Diagnosis: Greater awareness among healthcare professionals and advancements in diagnostic techniques are supporting early detection and treatment.

• Growing Demand for Effective Treatments: The risk of disease progression to liver fibrosis, cirrhosis, and liver failure is increasing the demand for effective therapeutic interventions.

• Increasing Research and Investment: Rising pharmaceutical investment and clinical research activities are accelerating the development of innovative MASH treatments.

 

MASH Market Barriers

• High Treatment Development Costs: Extensive clinical trials and regulatory requirements increase the cost and complexity of developing new MASH therapies.

• Diagnostic Challenges: The asymptomatic nature of early-stage MASH and the limitations of non-invasive diagnostic methods may delay diagnosis and treatment.

• Limited Treatment Options: Despite recent therapeutic advances, treatment options remain limited for certain patient populations and stages of disease.

• Safety and Efficacy Concerns: Potential adverse effects, long-term safety uncertainties, and the need to demonstrate sustained clinical benefits may hinder therapy adoption.

• High Treatment Costs and Access Barriers: Expensive therapies, reimbursement limitations, and disparities in healthcare access may restrict patient uptake across markets.

 

Scope of the MASH Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key MASH Companies: Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharmaceuticals, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Altimmune, Inc., AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Madrigal Pharmaceuticals, GlaxoSmithKline, 89bio, Inc., Akero Therapeutics, Inc, Regeneron Pharmaceuticals, Hepagene (Shanghai) Co., Ltd., Inventiva Pharma, Hanmi Pharmaceutical, Madrigal Pharmaceuticals, Inc., Sinew Pharma Inc., Boston Pharmaceuticals, and others

• Key MASH Therapies: Lanifibranor, Saroglitazar Magnesium, Semaglutide, VK2809, MGL-3196, HPG1860, Vonafexor (EYP001), Belapectin, Pegozafermin, Efruxifermin (EFX), DA-1241, NNC0194, J2H-1702, HSK31679, Pemvidutide, AZD9550, Survodutide, Namodenoson, Resmetirom, GSK4532990, BIO89-100, EFX, ALN-HSD, HPG1860, IVA337, HM15211, MGL-3196, SNP-610, BOS-580, and others

• MASH Therapeutic Assessment: MASH current marketed and MASH emerging therapies

• MASH Market Dynamics: MASH market drivers and MASH market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• MASH Unmet Needs, KOL’s views, Analyst’s views, MASH Market Access and Reimbursement

 

To know more about MASH companies working in the treatment market, visit @ MASH Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. MASH Market Report Introduction

2. Executive Summary for MASH

3. SWOT analysis of MASH

4. MASH Patient Share (%) Overview at a Glance

5. MASH Market Overview at a Glance

6. MASH Disease Background and Overview

7. MASH Epidemiology and Patient Population

8. Country-Specific Patient Population of MASH

9. MASH Current Treatment and Medical Practices

10. MASH Unmet Needs

11. MASH Emerging Therapies

12. MASH Market Outlook

13. Country-Wise MASH Market Analysis (2022 –2036)

14. MASH Market Access and Reimbursement of Therapies

15. MASH Market Drivers

16. MASH Market Barriers

17. MASH Appendix

18. MASH Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Nevada
State: LA
Country: India
Website: https://www.delveinsight.com/

After Decades in New York and Los Angeles, a Founder Comes Home to Canfield, Ohio, to Build a Small-Town Brand With a Hometown Giving Mission

Ella Vatour designs, produces and ships its personal care and sensory goods from Canfield, with purchases helping support nonprofit organizations in the community where the company began

Canfield, Ohio, USA - October 15, 2026 - Americans continue to start new businesses at a strong pace. According to U.S. Census Bureau data, more than 5.6 million business applications were filed in 2025, up from about 5.5 million the year before. Many of those new ventures are being built far from major business hubs, in the small towns their founders call home.

Ella Vatour is one of them. After roughly 30 years working in film, music and corporate roles in New York and Los Angeles, the company's founder returned to her hometown of Canfield, a small town in northeast Ohio, to reconnect with family. What began as handmade personal care products created for relatives has grown into a brand that is formulated, produced and shipped from a facility in Canfield.

"It never started as a business plan," said a spokesperson for Ella Vatour. "It started with family. A cousin asked for help, then a mom, then friends of friends. Coming home gave the brand its roots, and it made sense to build it right here, where it all began."

The company's offerings include personal care products made with ingredients such as grass-fed tallow and bakuchiol, alongside natural fragrance blends, jewelry, guidebooks and immersive sound experiences. Its central message, "Come Back to Your Senses," encourages people to step away from constant screens and notifications and slow down, even for a few minutes a day.

Giving back is built into the business. Through its Glow Up & Give Back initiative, purchases help support nonprofit organizations doing meaningful work in Canfield and the surrounding area.

"When you build something in a small town, you feel connected to the people around you," the spokesperson said. "Every order we pack here supports the community that raised us. That matters more to us than any big city address ever could."

For Ella Vatour, staying local is a deliberate choice. Producing and fulfilling orders in Canfield keeps every step of the process close to home, from the first batch to the final package, and allows the company to grow alongside the community it serves.

More information is available at ellavatour.com.

About Ella Vatour

Ella Vatour is a small business based in Canfield, Ohio, offering personal care products, natural fragrance blends, jewelry, guidebooks and immersive sound experiences. All products are formulated, produced and shipped from its Canfield facility. Through its Glow Up & Give Back initiative, purchases help support local nonprofit organizations. The company's mission is to help people come back to their senses and make everyday life feel a little more intentional.

Company Name: Ella Vatour

Contact Person: John Watson (PR Agent)

Website: https://www.ellavatour.com

Media Contact
Company Name: Ella Vatour
Contact Person: John Watson
Email:Send Email
Country: United States
Website: https://www.ellavatour.com

Open Enrollment Starts November 1: Tampa Broker Ryan Michalek Urges Families and the Self-Employed to Check 2027 Costs Before They Auto-Renew

Ryan Michalek, founder of Michalek Health Solutions, an independent health and life insurance brokerage in Tampa, Florida.

The independent licensed agent says a renewal notice is a prompt to re-shop, and December 15 is the date to circle for coverage that starts January 1.

Tampa, Florida, United States - October 15, 2026 - Open Enrollment for 2027 health coverage begins November 1, 2026. Ryan Michalek, founder of Michalek Health Solutions, an independent health and life insurance brokerage in Tampa licensed in 31 states, is asking families, freelancers and small business owners who buy their own coverage to look at their 2027 numbers before last year's plan renews on its own.

In states that use the federal Health Insurance Marketplace, Florida included, the window runs from November 1, 2026 to January 15, 2027. To have coverage start January 1, 2027, people need to enroll by December 15, 2026. States that run their own exchange can set their own dates, so residents of those states should confirm their deadline.

"When you work for yourself, nobody from HR sends the reminder," Michalek said. "A renewal notice is a prompt to re-shop, not an instruction to accept the increase. Look before November, not during it, and you get to make the call calm instead of rushed."

Health plans re-price every plan year. The premium, the deductible, the out-of-pocket maximum and the network can all change at renewal, and the plan that fit best last year isn't automatically the best fit this year. Letting a plan auto-renew means keeping it without seeing what changed.

Before Open Enrollment opens, Michalek walks clients through five checks:

1. Read the renewal notice line by line: premium, deductible, out-of-pocket maximum and network.
2. Update the income estimate. For self-employed people buying through the Marketplace, it shapes what help, if any, they qualify for.
3. Check that current doctors and prescriptions still appear in the plan's network and drug list.
4. Mark December 15 for a January 1 start.
5. Compare before deciding, including whether keeping the current plan is the right call.

"Sometimes keeping your current plan is the right call, and I'll tell you so," Michalek said. "What I don't want is anybody finding out in January what changed in November."

For people who buy their own coverage, Michalek Health Solutions compares options across many insurers, and there is no fee to the client; the agency is paid by the carriers. Private under-65 plans can often be applied for outside the Open Enrollment window, but many are medically underwritten, so approval isn't automatic.

Michalek's guides cover the 2027 dates in more detail, what to do when a premium goes up at renewal, and how to map options before a call:

• Open Enrollment 2027 guide: https://michalekhealthsolutions.com/open-enrollment/
• When your premium goes up: https://michalekhealthsolutions.com/health-insurance-premium-increase/
• Coverage cost estimator: https://michalekhealthsolutions.com/coverage-cost-estimator/
• Families and individuals: https://michalekhealthsolutions.com/family-health-insurance/
• About Ryan Michalek: https://michalekhealthsolutions.com/about-ryan/

Disclosure

Ryan Michalek is a licensed health and life insurance agent, NPN 21043091. Michalek Health Solutions is not affiliated with or endorsed by any government agency or the federal Health Insurance Marketplace. This release is an advertisement for insurance. It is not an offer or guarantee of coverage. Plan availability, benefits and rates vary by state and individual eligibility.

About Michalek Health Solutions

Michalek Health Solutions is an independent health and life insurance brokerage based in Tampa, Florida, founded by Ryan Michalek and licensed across 31 states (NPN 21043091). It is an independent, one-person practice that has grown largely through client referrals, specializing in private under-65 health coverage for the self-employed, families, and small business owners, with no fee to the client.

Media Contact
Company Name: Michalek Health Solutions
Contact Person: Ryan Michalek
Email:Send Email
Phone: (813) 833-7448
Address:5701 E Hillsborough Ave Ste 1202
City: Tampa
State: Florida
Country: United States
Website: https://michalekhealthsolutions.com